Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 28, 2007

Applied Biosystems and MDS SCIEX Launched Software Development Initiative

  • Applied Biosystems and MDS Sciex launched a new software development initiative to improve the abilities of pharmaceutical companies to determine drug candidate viability early in the development pipeline.

    To help lower the costly drug-candidate failure rate within the pharmaceutical industry, Applied Biosystems/MDS SCIEX's software will focus on improving the timeliness and accuracy of information generated during ADME testing of the substances that can be developed into drugs.

    Applied Biosystems/MDS SCIEX is collaborating with Sound Analytics and Pfizer to design these software applications. Sound Analytics will provide expertise in early ADME software development to complement Applied Biosystems/MDS SCIEX's expertise in drug research tools and software-based automation. Pfizer will provide the guidance to shape the requirements for the new ADME software applications.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »